The effect of DASH diet in subjects with metabolic syndrome

The effect of dietary approaches to stop hypertension (DASH) diet on metabolic syndrome components and hepatic steatosis indices in subjects with metabolic syndrome

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180201038585N12

Enrollment

Registered

2022-10-21

Start date

2022-10-22

Completion date

Unknown

Last updated

2023-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic syndrome. Metabolic syndrome

Interventions

Intervention 1: Intervention group: The intervention group will receive DASH (Dietary Approaches to Stop Hypertension) diet. This diet contains 52 to 55% carbohydrates, 16 to 18% protein and 30% fat.

Eligibility

Sex/Gender

All

Age

30 Years to 60 Years

Inclusion criteria

Inclusion criteria: Age 30-60 years Diagnosis of Metabolic Syndrome based on IDF criteria Sign of informed written consent

Exclusion criteria

Exclusion criteria: Pregnancy and lactation Hereditary hemochromatosis History of gingival or gastroplasty bypass surgery Use of hepatotoxic drugs such as calcium channel blocker and high doses of synthetic estrogens Patients with hypothyroidism Cushing syndrome Kidney failure and kidney stone Cardiovascular disease History of hepatitis B and C Wilson disease

Design outcomes

Primary

Measure	Time frame
Diastolic Blood Pressure. Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Sphygmomanometer.	—

Secondary

Measure	Time frame
Waist Circumference. Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Meter.;Triglyceride. Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Enzymatic method.;High density lipoprotein cholesterol. Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Enzymatic method.;Systolic blood pressure. Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Sphygmomanometer.;Fasting blood glucose. Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Enzymatic method.;Low density lipoprotein cholesterol. Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Enzymatic method.;Total Cholesterol. Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Enzymatic method.;Alanine Aminotransferase. Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Enzymatic method.;Aspartat transaminase. Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Enzymatic method.;Weight. Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Scale.;Body mass index. Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Formula.;Hepatic steatosis index. Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Formula.;Lipid accumulation product. Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Formula.;Visceral adiposity index. Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Formula.;Fatty liver index. Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Formula.;Gamma-glutamyl transpeptidase. Timepoint: Before intervention and 12 weeks after th	—

Measure

Time frame

Waist Circumference. Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Meter.;Triglyceride. Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Enzymatic method.;High density lipoprotein cholesterol. Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Enzymatic method.;Systolic blood pressure. Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Sphygmomanometer.;Fasting blood glucose. Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Enzymatic method.;Low density lipoprotein cholesterol. Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Enzymatic method.;Total Cholesterol. Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Enzymatic method.;Alanine Aminotransferase. Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Enzymatic method.;Aspartat transaminase. Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Enzymatic method.;Weight. Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Scale.;Body mass index. Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Formula.;Hepatic steatosis index. Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Formula.;Lipid accumulation product. Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Formula.;Visceral adiposity index. Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Formula.;Fatty liver index. Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Formula.;Gamma-glutamyl transpeptidase. Timepoint: Before intervention and 12 weeks after th

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactKarim Parastouei

Bagheiat-allah University of Medical Sciences

parastouei@gmail.com+98 21 8248 3264

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 27, 2026